Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Viola A Heinzelmann-SchwarzAndré B KindMarcus VetterKenneth RussellSiti OmarAndreas SchoetzauKerstin HoeckDaniel FinkMichael L FriedlanderNeville F Hacker

Published in: Journal of cancer research and clinical oncology (2020)

Early stage I/II MMMT-E patients have excellent prognosis if no recurrence has appeared within the first 2.5 years. In MMMT-E, platinum/anthracycline or ifosfamide regimen associated with better outcomes than platinum/taxanes regimens. This might also apply to MMMT-O.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
early stage
peritoneal dialysis
prognostic factors
type diabetes
squamous cell carcinoma
radiation therapy
patient reported outcomes
adipose tissue
patient reported